drugset / Trial / NCT01207128
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive aspergillosis (IA) in patients with hematological cancer.
Timeline
- Start
- 2011-02
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Micafungin | Peptide | 100 mg | Intravenous |
| Comparator | Voriconazole | Small molecule | 4 mg/kg | Intravenous |
| Comparator | Voriconazole | Small molecule | 200 mg | Intravenous |